Neo Ivy Capital Management Increases Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Neo Ivy Capital Management grew its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 501.6% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 395,745 shares of the biopharmaceutical company's stock after buying an additional 329,959 shares during the period. Amicus Therapeutics makes up 0.8% of Neo Ivy Capital Management's investment portfolio, making the stock its 27th largest holding. Neo Ivy Capital Management owned about 0.13% of Amicus Therapeutics worth $3,727,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of FOLD. Virtus Fund Advisers LLC acquired a new position in shares of Amicus Therapeutics during the 4th quarter valued at $29,000. Covestor Ltd increased its stake in Amicus Therapeutics by 114.9% in the fourth quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company's stock valued at $41,000 after purchasing an additional 2,312 shares in the last quarter. R Squared Ltd acquired a new position in shares of Amicus Therapeutics during the fourth quarter valued at about $79,000. KBC Group NV boosted its position in shares of Amicus Therapeutics by 44.4% during the 4th quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company's stock worth $96,000 after purchasing an additional 3,120 shares in the last quarter. Finally, Sciencast Management LP acquired a new stake in shares of Amicus Therapeutics in the 4th quarter valued at about $100,000.

Amicus Therapeutics Stock Down 0.6%

NASDAQ FOLD traded down $0.04 on Monday, reaching $6.22. The company had a trading volume of 2,822,292 shares, compared to its average volume of 2,840,115. The company has a quick ratio of 2.42, a current ratio of 3.39 and a debt-to-equity ratio of 2.01. The company's fifty day moving average is $7.11 and its 200 day moving average is $8.71. Amicus Therapeutics, Inc. has a 52-week low of $5.81 and a 52-week high of $12.65. The stock has a market capitalization of $1.92 billion, a P/E ratio of -34.56, a P/E/G ratio of 1.51 and a beta of 0.64.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. Wells Fargo & Company dropped their price target on Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating on the stock in a research note on Thursday, February 20th. Wall Street Zen lowered Amicus Therapeutics from a "buy" rating to a "hold" rating in a research report on Monday, May 5th. The Goldman Sachs Group cut their target price on Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating on the stock in a report on Friday, May 2nd. Needham & Company LLC restated a "hold" rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. Finally, UBS Group upped their price objective on shares of Amicus Therapeutics from $21.00 to $22.00 and gave the stock a "buy" rating in a report on Friday, May 2nd. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $16.22.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.